{"article_title": "Analyst upgrades Gilead, says biotech is 'too good not to own'", "article_keywords": ["biotech", "c", "good", "twitter", "company", "sales", "hepatitis", "gilead", "upgrade", "drug", "upgrades", "report", "analyst", "market"], "article_url": "http://blogs.marketwatch.com/health-exchange/2014/02/04/analyst-upgrades-gilead-says-biotech-is-too-good-not-to-own/", "article_text": "Shares of Gilead Sciences Inc. got a 4% lift from an analyst\u2019s glowing report and upgrade of the biotechnology firm Tuesday, as the company prepares to report fourth-quarter earnings after the close.\n\nGilead /quotes/zigman/72849/delayed /quotes/nls/gild GILD shares added $3 to $81.83 in recent action after Brian P. Skorney, analyst at Robert W. Baird, upgraded the Foster City, Calif.-based company to outperform from neutral.\n\nBloomberg A machine purifies hepatitis C drug at Gilead lab.\n\nSkorney said the outlook for sales of its new hepatitis C drug, Sovaldi, is sunny. Gilead is considered now to be the frontrunner to sell the first such medication as it is farther along in getting its drug to market. AbbVie Inc. /quotes/nls/abbv ABBV is close behind with tests nearly finished on its hepatitis C drug. Further, Gilead is testing and is expected to launch an updated hepatitis C drug \u2014 a combination of substances known as sofosbuvir and ledipisvir \u2014 next year.\n\nHeadlining his report by saying Gilead\u2019s position in the hepatitis C market means the company is \u201ctoo good not to own,\u201d Skorney said the company is seeing \u201coverwhelmingly positive\u201d prescription drug trends.\n\n\u201cSovaldi prescriptions, to date, are outperforming our expectations by a multiple,\u201d he said in a note to clients. \u201cWe believe current trends indicate that 2014/2015 consensus hep C sales are [less than] 50% of what Gilead will report. We think the sofosbuvir/ledipisvir combo will have higher peak sales than any historical pharma product and will do so in year one.\u201d\n\nSkorney says Gilead\u2019s ventures into the HIV market are strong as well, with sales of its Atripia drug expected to help push the company past analyst forecasts on sales.\n\nFollow Russ Britt on Twitter @russbrittmktw\n\nFollow Health Exchange on Twitter @MWHealthBlog\n\nMore health-care news from MarketWatch:\n\nCBO says Obamacare will add to deficit\n\nPfizer leads Dow after upgrade on promising cancer drug\n\nNFL players tout Obamacare for president", "article_metadata": {"article.created": "2014-02-04T14:06:11-05:00", "application-name": "MarketWatch.com", "twitter": {"domain": "Marketwatch.com", "description": "Shares of Gilead Sciences Inc. get a 4% lift from an analyst's glowing report and upgrade on the biotechnology firm, as the company prepares to report fourth-quarter earnings.", "title": "Analyst upgrades Gilead, says biotech is \u2018too good not to own\u2019", "url": "http://blogs.marketwatch.com/health-exchange/2014/02/04/analyst-upgrades-gilead-says-biotech-is-too-good-not-to-own/", "image": {"src": "http://s.wsj.net/public/resources/MWimages/MW-BT750_hepati_MG_20140131100519.jpg"}, "site": "MarketWatch", "card": "summary_large_image"}, "article.author": "Russ Britt", "article.section": "Markets", "keywords": "biotechnology,earnings,Gilead Sciences Inc.,health care,hepatitis C drug", "article.headline": "Analyst upgrades Gilead, says biotech is \u2018too good not to own\u2019", "msapplication-task": "name=SmartMoney;action-uri=http://www.smartmoney.com/;icon-uri=http://www.smartmoney.com/favicon.ico", "description": "Shares of Gilead Sciences Inc. get a 4% lift from an analyst's glowing report and upgrade on the biotechnology firm, as the company prepares to report fourth-quarter earnings.", "author": "Russ Britt", "article.page": "Health Exchange Blog", "news_keywords": "biotechnology,earnings,Gilead Sciences Inc.,health care,hepatitis C drug", "article.published": "2014-02-04T14:06:11-05:00", "ROBOTS": "noarchive, noodp", "msapplication-tooltip": "MarketWatch", "fb": {"url": "http://blogs.marketwatch.com/health-exchange/2014/02/04/analyst-upgrades-gilead-says-biotech-is-too-good-not-to-own/", "app_id": 283204329838}, "article": {"publisher": "https://www.facebook.com/marketwatch", "image_count": 2}, "og": {"site_name": "Marketwatch", "description": "Shares of Gilead Sciences Inc. get a 4% lift from an analyst's glowing report and upgrade on the biotechnology firm, as the company prepares to report fourth-quarter earnings.", "title": "Analyst upgrades Gilead, says biotech is \u2018too good not to own\u2019", "url": "http://blogs.marketwatch.com/health-exchange/2014/02/04/analyst-upgrades-gilead-says-biotech-is-too-good-not-to-own/", "image": {"width": 569, "identifier": "http://s.wsj.net/public/resources/MWimages/MW-BT750_hepati_MG_20140131100519.jpg", "height": 398}, "type": "article"}, "article.access": "free", "article.type": "Health Exchange", "article.id": "BL-MW243B-1994", "article.updated": "2014-02-04T14:06:11-05:00"}, "_id": "\"57477af36914bd0286fd070d\"", "article_summary": "Bloomberg A machine purifies hepatitis C drug at Gilead lab.\nAbbVie Inc. /quotes/nls/abbv ABBV is close behind with tests nearly finished on its hepatitis C drug.\n\u201cWe believe current trends indicate that 2014/2015 consensus hep C sales are [less than] 50% of what Gilead will report.\nFurther, Gilead is testing and is expected to launch an updated hepatitis C drug \u2014 a combination of substances known as sofosbuvir and ledipisvir \u2014 next year.\nSkorney said the outlook for sales of its new hepatitis C drug, Sovaldi, is sunny."}